Moonlight AI was created to democratize the access to genomic information that is essential for therapy decision making in the era of personalized medicine. The four co-founders of Moonlight AI believe that every cancer patient in the world shall have access to the genomic information of its tumor since it is required for selecting the right treatment.
Hematologic cancers affect roughly 1.7 million people worldwide. With the advancement of precision medicine, today’s workflow additionally incorporates additional genomic information from Next-Generation Sequencing (NGS) in order to match the patient to available targeted therapies. However, access to genomic information is currently limited by proximity to NGS instruments and the high cost of NGS testing.
The mission of Moonlight AI is democratizing access to genomic insight at a fraction of the
time and cost by using computer vision to identify genomic aberrations directly from the blood or bone marrow smear the hematologist uses.
The AI based models allow not only faster and more affordable diagnosis, but also response assessment and relapse detection. Ultimately AI based models will help the hematologists to determine and continuously follow-up which treatment option is the best for individual cancer
patients at any point of the patient journey.